drugset / Trial / NCT06054191
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, two parallel group study assessing the efficacy and safety of neoadjuvant and adjuvant targeted therapy in patients with stage IB-IIIA NSCLC harboring BRAF V600 or MET exon14 mutations.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-03-01
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capmatinib | Small molecule | 400 mg | — |
| Subject | Dabrafenib | Small molecule | 150 mg | — |
| Subject | Trametinib | Small molecule | 2 mg | — |